The next generation of antibody-drug conjugates comes of age.
Beck
Alain
A
Department of Physico-Chemistry, Centre d'Immunologie Pierre Fabre (CIPF), St Julien-en-Genevois 74164, France. alain.beck@pierre-fabre.com
Haeuw
Jean-François
JF
Wurch
Thierry
T
Goetsch
Liliane
L
Bailly
Christian
C
Corvaïa
Nathalie
N
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates